Vericel Turns Profitable in Q2, Authorizes $200M Buyback, and Locks in BARDA Pact
VCEL sits 68% above its 52-week low of $28.95.
Summary
Vericel posted Q2 net income of $2.2M on revenue of $77.5M, authorized a $200M share buyback, and updated progress on its BARDA agreement for NexoBrid.
Key Events · Earnings and Guidance · VCEL
-
Q2 Profitability Achieved
Revenue of $77.5M, up 22% year-over-year, drove net income to $2.2M ($0.04/share), reversing a loss of $0.6M a year ago. Gross margin came in at 72.8%, compared with 73.7% in the prior-year period.
-
$200M Share Repurchase Authorized
The board approved the company's first buyback program, which carries no expiration date. Repurchases may be executed in the open market or through private transactions.
-
BARDA Agreement Valued at Up to $196.9M
A ten-year agreement with BARDA provides $34.9M in base funding for NexoBrid procurement and development. No revenue was recognized in Q2.
-
Strong Cash Position
Cash, equivalents, and investments totaled $227.5M at quarter-end, with no outstanding borrowings under the $150M revolving credit facility.
Analysis · VCEL · Life Sciences
A return to profitability on 22% revenue growth, fueled by MACI and Epicel, marks a pivotal quarter for Vericel. Underscoring management's confidence in cash generation and valuation, the board authorized the company's first-ever share repurchase program at $200 million. Meanwhile, the BARDA agreement opens a government-funded growth path for NexoBrid, though no revenue has been booked yet. Together, improving fundamentals and a new capital-return policy represent a meaningful positive shift for shareholders.
At the time of this filing, VCEL was trading at $48.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $28.95 to $48.75. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.